¿ Cytel Corp., of San Diego, licensed its carbohydrate synthesis and manufacturing technology to Deerfield, Ill.-based Baxter Healthcare Corp.¿s Nextran unit for exclusive use in transplantation. The $4 million license agreement supercedes existing supply agreements between the companies.

¿ Gliatech Inc., of Cleveland, completed a Phase I trial of GT2331, its histamine H3 antagonist, and began a rising multiple-dose study of the same compound. The drug is being developed for central nervous system diseases involving attention and sleep disorders.

¿ Hollis-Eden Pharmaceuticals Inc., of San Diego, said it received FDA clearance to begin dosing in a Phase I/II trial of the HIV drug HE2000. The drug is believed to work by inhibiting the host cell¿s energy-producing enzymes.

¿ Immunex Inc., of Seattle, said expanded Phase II trials of Nuvance (IL-4 receptor) for the long-term control of asthma will start in the second quarter. Development is being expedited based on results of the first multi-dose trial.

¿ Cadus Pharmaceuticals Inc., of Tarrytown, N.Y., said the U.S. District Court in San Diego denied its motion to overturn a jury verdict in its patent infringement lawsuit with Sibia Neurosciences Inc., of La Jolla, Calif. The court also denied Cadus¿ motions to grant a new trial or set aside the $18 million damage award. Cadus said it will appeal.

¿ Chiroscience Group plc, of London, said it received an approvable letter from the FDA for its long-acting local anesthetic, Chirocaine. The company is discussing final labeling issues with the agency.

No Comments